期刊
BJPSYCH OPEN
卷 8, 期 4, 页码 -出版社
CAMBRIDGE UNIV PRESS
DOI: 10.1192/bjo.2022.537
关键词
Antipsychotics; psychotic disorders; schizophrenia; COVID-19; clozapine
类别
资金
- National Institute for Health Research (NIHR) Imperial Biomedical Research Centre (BRC)
- Medical Research Council (MRC) London Institute of Medical Sciences
- Wellcome Trust [201486/Z/16/Z]
- MQ: Transforming Mental Health [MQDS17/40]
- MRC UK [MR/S037675/1, MR/W014416/1]
- BMA Foundation
- MRC [MC_PC_17213, MR/W014386/1]
- NIHR Imperial BRC
- NIHR Cambridge BRC [BRC-1215-20014]
Patients receiving clozapine were more likely to be tested for COVID-19, but not to test positive. Increased testing in patients receiving clozapine suggests prudent judgement by clinicians, considering the overall health vulnerabilities of this group.
The antipsychotic clozapine is known to have immune-modulating effects. Clozapine treatment has been reported to be associated with increased risk of COVID-19 infection. However, it remains unclear whether this is because of increased testing of this patient group, who are closely monitored. We linked anonymised health records from mental health services in Cambridgeshire (UK), for patients taking antipsychotic medication, with data from the local COVID-19 testing hub. Patients receiving clozapine were more likely to be tested for COVID-19, but not to test positive. Increased testing in patients receiving clozapine suggests prudent judgement by clinicians, considering the overall health vulnerabilities of this group.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据
分享论文
